Online inquiry

IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3492MR)

This product GTTS-WQ3492MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3492MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12660MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ8008MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GZ-402668
GTTS-WQ9143MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMGN-289
GTTS-WQ846MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-155
GTTS-WQ3334MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AT-001
GTTS-WQ9116MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMGN242
GTTS-WQ15431MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TSR-033
GTTS-WQ15846MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA XmAb-18087
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW